Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops

Molecular Nutrition and Food Research

Volumn 58, Issue 2, 2014, Pages 248-255

  Legette, Leecole ^a,b   Karnpracha, Chanida ^b   Reed, Ralph L ^a,b   Choi, Jaewoo ^a,b   Bobe, Gerd ^a,b   Christensen, J Mark ^b   Rodriguez Proteau, Rosita ^b   Purnell, Jonathan Q ^c   Stevens, Jan F ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Flavonoids; Hops; Human metabolism; Pharmacokinetics; Xanthohumol

Indexed keywords

6 PRENYLNARINGENIN; 6-PRENYLNARINGENIN; 8 PRENYLNARINGENIN; 8-PRENYLNARINGENIN; ANTIDIABETIC AGENT; FLAVANONE DERIVATIVE; FLAVONOID; ISOXANTHOHUMOL; PROPIOPHENONE DERIVATIVE; XANTHOHUMOL; XANTHONE DERIVATIVE;

ADULT; ARTICLE; BLOOD; CHEMISTRY; DOSE RESPONSE; FEMALE; HALF LIFE TIME; HOPS; HUMAN; HUMAN METABOLISM; HUMULUS; LIQUID CHROMATOGRAPHY; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; TANDEM MASS SPECTROMETRY;

FLAVONOIDS; HOPS; HUMAN METABOLISM; PHARMACOKINETICS; XANTHOHUMOL;

ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVANONES; FLAVONOIDS; HALF-LIFE; HUMANS; HUMULUS; HYPOGLYCEMIC AGENTS; MALE; PROPIOPHENONES; TANDEM MASS SPECTROMETRY; XANTHONES;

EID: 84893397732     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300333     Document Type: Article

References (31)

1. American Diabetes Association, Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013, 36, 1033-1046.
2. Chiha, M., Njeim, M., Chedrawy, E. G., Diabetes and coronary heart disease: a risk factor for the global epidemic. Int. J. Hypertens. 2012, 2012, 697240.
3. Cumbie, B. C., Hermayer, K. L., Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc. Health Risk. Manag. 2007, 3, 823-832.
4. Nicolle, E., Souard, F., Faure, P., Boumendjel, A., Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship. Curr. Med. Chem. 2012, 18, 2661-2672.
5. Legette, L. L., Moreno Luna, A. Y., Reed, R. L., Miranda, C. L. et al., Xanthohumol lowers body weight and fasting plasma glucose in obese male Zucker fa/fa rats. Phytochemistry 2013, 91, 236-241.
6. Nozawa, H., Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem. Biophys. Res. Commun. 2005, 336, 754-761.
7. Miranda, C. L., Stevens, J. F., Ivanov, V., McCall, M. et al., Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J. Agric. Food Chem. 2000, 48, 3876-3884.
8. Lupinacci, E., Meijerink, J., Vincken, J. P., Gabriele, B. et al., Xanthohumol from hop (Humulus lupulus L.) is an efficient inhibitor of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha release in LPS-stimulated RAW 264.7 mouse macrophages and U937 human monocytes. J. Agric. Food Chem. 2009, 57, 7274-7281.
9. Peluso, M. R., Miranda, C. L., Hobbs, D. J., Proteau, R. R. et al., Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2). Planta Med. 2010, 76, 1536-1543.
10. Gerhauser, C., Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites. Mol. Nutr. Food Res. 2005, 49, 827-831.
11. Xuan, N. T., Shumilina, E., Gulbins, E., Gu, S. et al., Triggering of dendritic cell apoptosis by xanthohumol. Mol. Nutr. Food Res. 2010, 54, S214-S224.
12. Milligan, S., Kalita, J., Pocock, V., Heyerick, A. et al., Oestrogenic activity of the hop phyto-oestrogen, 8-prenylnaringenin. Reproduction 2002, 123, 235-242.
13. Milligan, S. R., Kalita, J. C., Heyerick, A., Rong, H. et al., Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J. Clin. Endocrinol. Metab. 1999, 84, 2249-2252.
14. Milligan, S. R., Kalita, J. C., Pocock, V., Van De Kauter, V. et al., The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J. Clin. Endocrinol. Metab. 2000, 85, 4912-4915.
15. Stevens, J. F., Page, J. E., Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry 2004, 65, 1317-1330.
16. Guo, J., Nikolic, D., Chadwick, L. R., Pauli, G. F. et al., Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.). Drug Metab. Dispos. 2006, 34, 1152-1159.
17. Bolca, S., Possemiers, S., Maervoet, V., Huybrechts, I. et al., Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br. J. Nutr. 2007, 98, 950-959.
18. Possemiers, S., Bolca, S., Grootaert, C., Heyerick, A. et al., The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J. Nutr. 2006, 136, 1862-1867.
19. Possemiers, S., Heyerick, A., Robbens, V., De Keukeleire, D. et al., Activation of proestrogens from hops (Humulus lupulus L.) by intestinal microbiota; conversion of isoxanthohumol into 8-prenylnaringenin. J. Agric. Food Chem. 2005, 53, 6281-6288.
20. Kirkwood, J. S., Legette, L. L., Miranda, C. L., Jiang, Y. et al., A metabolomics driven elucidation of the anti-obesity mechanisms of xanthohumol. J. Biol. Chem. 2013, 288, 19000-19013.
21. Fairley, B., Botting, N.P., Cassidy, A., The synthesis of daidzein sulfates. Tetrahedron 2003, 59, 5407-5410.
22. Soidinsalo, O., Wahala, K., Synthesis of phytoestrogenic isoflavonoid disulfates. Steroids 2004, 69, 613-616.
23. Legette, L., Ma, L., Reed, R. L., Miranda, C. L. et al., Pharmacokinetics of xanthohumol and metabolites in rats after oral and intravenous administration. Mol. Nutr. Food Res. 2012, 56, 466-474.
24. Beekmann, K., Actis-Goretta, L., van Bladeren, P. J., Dionisi, F. et al., A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids. Food Funct. 3, 1008-1018.
25. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003, Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070124.pdf. Accessed on February 27, 2013.
26. Egert, S., Wolffram, S., Bosy-Westphal, A., Boesch-Saadatmandi, C. et al., Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J. Nutr. 2008, 138, 1615-1621.
27. Hosoda, K., Furuta, T., Ishii, K., Metabolism and disposition of isoflavone conjugated metabolites in humans after ingestion of kinako. Drug Metab. Dispos. 39, 1762-1767.
28. Rufer, C. E., Bub, A., Moseneder, J., Winterhalter, P. et al., Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study. Am. J. Clin. Nutr. 2008, 87, 1314-1323.
29. Setchell, K. D., Clerici, C., Equol: pharmacokinetics and biological actions. J. Nutr. 140, 1363S-1368S.
30. Shargel, L., Wu-Pong, S., Yu, A., Applied Biopharmaceutics and Pharmacokinetics, McGraw-Hill Companies, New York, NY 2012, pp. 153-157.
31. Tang, H., Hussain, A., Leal, M., Mayersohn, M. et al., Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab. Dispos. 2007, 35, 1886-1893.